8-K: Orthofix Medical Secures $275 Million Credit Facility with Oxford Finance

Orthofix Medical Inc. has entered into a $275 million secured credit agreement with Oxford Finance LLC and other lenders, including a $160 million term loan and a $65 million delayed draw term loan facility.

Summary

• Orthofix Medical Inc. has secured a $275 million credit facility with Oxford Finance LLC, which includes a $160 million senior secured term loan and a $65 million senior secured delayed draw term loan facility.
• The delayed draw term loan can be accessed between January 1, 2025, and June 30, 2026, contingent on maintaining a debt-to-EBITDA leverage ratio below 4.0x.
• An additional $50 million of draw capacity is available at Oxford's discretion until January 1, 2029.
• The loans will mature in November 2029, with an interest-only period until December 2028, followed by monthly amortization.
• The credit facilities are secured by a first priority lien on substantially all assets of the company and its guarantors, including U.S. intellectual property.
• Borrowings bear interest at the greater of 8.75% or 5.75% plus the one-month term SOFR rate.
• A 1.5% facility fee is due at funding, and a 0.5% unused line fee is payable annually on the delayed draw term loan.
• The agreement includes financial covenants such as maintaining at least $45 million of unrestricted cash at the initial funding and $15 million thereafter, and a maximum debt-to-EBITDA leverage ratio of 4.0x.
• The company has also terminated its previous financing agreement with Blue Torch Finance, LLC.

Sentiment

Score: 7

Explanation: The document is generally positive as it secures significant funding for the company, but there are some risks associated with the debt and financial covenants. The sentiment is therefore moderately positive.

Positives

• The new credit facility provides Orthofix with significant capital for operations and growth.
• The delayed draw term loan provides flexibility in accessing additional funds as needed.
• The interest-only period until December 2028 allows for better cash flow management in the near term.
• The termination of the previous financing agreement simplifies the company's capital structure.

Negatives

• The credit facility is secured by a first priority lien on substantially all assets, which could limit future financial flexibility.
• The interest rate is relatively high, at a minimum of 8.75%, which could increase borrowing costs.
• The company is subject to financial covenants, including maintaining a minimum cash balance and a maximum debt-to-EBITDA ratio, which could restrict operations if not met.

Risks

• Failure to maintain the required cash balance or debt-to-EBITDA ratio could trigger an event of default.
• The company's ability to draw on the delayed draw term loan is contingent on meeting certain financial conditions.
• The high interest rate could increase the company's financial burden.
• The first priority lien on substantially all assets could limit the company's ability to secure additional financing in the future.

Future Outlook

The document outlines the terms of the credit facility and provides guidance on financial covenants, but does not include specific forward-looking statements about the company's future performance or growth.

Industry Context

This announcement reflects a common financing strategy for medical device companies seeking capital for growth and operations. The use of a secured credit facility with a combination of term loans and delayed draw options is typical in this sector.

Comparison to Industry Standards

• The interest rate of 8.75% or 5.75% plus SOFR is within the typical range for secured loans in the medical device industry, but may be considered high depending on the company's credit profile and market conditions.
• The debt-to-EBITDA leverage ratio of 4.0x is a common financial covenant in such agreements, but the specific level may vary based on the company's size, profitability, and risk profile.
• The use of a first priority lien on substantially all assets is a standard practice for secured lending, providing lenders with a strong claim on the company's assets in case of default.
• Comparable companies in the medical device sector often utilize similar financing structures, including term loans, revolving credit facilities, and delayed draw options, to fund acquisitions, research and development, and working capital needs.

Stakeholder Impact

• Shareholders may view the new credit facility positively as it provides capital for growth, but may also be concerned about the increased debt and financial covenants.
• Employees may benefit from the company's improved financial position and ability to invest in operations.
• Customers may see improved product development and service capabilities due to the increased funding.
• Suppliers may benefit from the company's increased financial stability and ability to pay for goods and services.
• Creditors may be concerned about the company's increased debt burden and the first priority lien on substantially all assets.

Next Steps

• The company will draw down the initial $160 million term loan.
• The company will need to maintain compliance with the financial covenants outlined in the agreement.
• The company may draw on the $65 million delayed draw term loan facility between January 1, 2025, and June 30, 2026.
• The company may access an additional $50 million of draw capacity at Oxford's discretion until January 1, 2029.

Key Dates

Keywords

credit facility, term loan, secured loan, debt financing, EBITDA, leverage ratio, Oxford Finance, Orthofix Medical, financial covenants, intellectual property